Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE R BEATO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1427017797
CMS profile
517655
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$1,244.47

7 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,014.51 3
Food and Beverage $229.96 4

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $1,244.47 7

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE R BEATO

NPI 1427017797 · CMS profile ID 517655

Allopathic & Osteopathic Physicians / Internal Medicine

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1427017797?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE R BEATO, NPI 1427017797, CMS profile ID 517655. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427017797?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JORGE R BEATO, NPI 1427017797, CMS profile ID 517655. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427017797?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JORGE R BEATO, NPI 1427017797, CMS profile ID 517655, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1427017797?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

7 matching records · $1,244.47 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 7 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–7 of 7.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $14.9902/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747131533 CMS
Takeda Pharmaceuticals U.S.A., Inc. $124.9902/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747131535 CMS
Takeda Pharmaceuticals U.S.A., Inc. $370.7502/21/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747131537 CMS
Takeda Pharmaceuticals U.S.A., Inc. $137.5002/21/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747131539 CMS
Takeda Pharmaceuticals U.S.A., Inc. $506.2602/21/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747131541 CMS
Takeda Pharmaceuticals U.S.A., Inc. $74.9902/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747131543 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.9902/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747131545 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $1,244.47 7
PY2021 $165.49 1
PY2022 $109.51 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $300,560.24 163
PY2024 Principal investigator $274,846.18 43
PY2023 Principal investigator $88,776.09 25
PY2022 Principal investigator $89,322.06 25
PY2021 Principal investigator $126,566.09 27
PY2020 Principal investigator $415,180.77 38
PY2019 Principal investigator $574,452.51 42

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

163 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 12/24/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638241
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 12/24/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638243
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 12/24/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638245
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 12/24/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638247
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 12/24/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638249
Principal investigator 1 Boehringer Ingelheim International GmbH $800.00 12/24/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638251
Principal investigator 1 Boehringer Ingelheim International GmbH $800.00 12/24/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638253
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 12/24/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638255
Principal investigator 1 Boehringer Ingelheim International GmbH $3,250.00 12/24/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638257
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 12/24/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638259
Principal investigator 1 Boehringer Ingelheim International GmbH $700.00 12/24/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638261
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 12/24/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638263
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 12/24/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638265
Principal investigator 1 Boehringer Ingelheim International GmbH $408.10 12/17/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220638029
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 12/17/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220638031
Principal investigator 1 Boehringer Ingelheim International GmbH $1,752.00 12/17/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220638033
Principal investigator 1 Boehringer Ingelheim International GmbH $58.62 12/17/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220638035
Principal investigator 1 Boehringer Ingelheim International GmbH $18.00 12/17/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220638037
Principal investigator 1 Boehringer Ingelheim International GmbH $233.20 12/17/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638271
Principal investigator 1 Boehringer Ingelheim International GmbH $876.00 12/17/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638273
Principal investigator 1 Boehringer Ingelheim International GmbH $48.85 12/17/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638275
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 12/17/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638277
Principal investigator 1 Madrigal Pharmaceuticals $200.00 12/11/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253818
Principal investigator 1 Madrigal Pharmaceuticals $100.00 12/11/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253822
Principal investigator 1 Madrigal Pharmaceuticals $5,346.00 12/11/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253826
Principal investigator 1 Madrigal Pharmaceuticals $4,033.00 12/11/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253830
Principal investigator 1 Madrigal Pharmaceuticals $2,428.29 11/25/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252837
Principal investigator 1 Madrigal Pharmaceuticals $2,428.29 11/07/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252408
Principal investigator 1 Boehringer Ingelheim International GmbH $11,134.80 10/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638221
Principal investigator 1 Boehringer Ingelheim International GmbH $6,238.49 10/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638223
Principal investigator 1 Boehringer Ingelheim International GmbH $5,054.40 10/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638225
Principal investigator 1 Boehringer Ingelheim International GmbH $5,054.40 10/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638227
Principal investigator 1 Boehringer Ingelheim International GmbH $10,729.80 10/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638229
Principal investigator 1 Boehringer Ingelheim International GmbH $6,543.45 10/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638231
Principal investigator 1 Boehringer Ingelheim International GmbH $7,391.45 10/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638233
Principal investigator 1 Boehringer Ingelheim International GmbH $5,054.40 10/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638235
Principal investigator 1 Boehringer Ingelheim International GmbH $5,054.40 10/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638237
Principal investigator 1 Boehringer Ingelheim International GmbH $10,729.80 10/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638239
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 10/27/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638267
Principal investigator 1 Boehringer Ingelheim International GmbH $3.00 10/27/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638269
Principal investigator 1 Madrigal Pharmaceuticals $4,856.58 10/16/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251508
Principal investigator 1 GlaxoSmithKline, LLC. $4,526.80 10/02/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192168038
Principal investigator 1 Madrigal Pharmaceuticals $1,950.75 09/23/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250542
Principal investigator 1 Madrigal Pharmaceuticals $7,695.00 09/23/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250546
Principal investigator 1 Madrigal Pharmaceuticals $4,586.50 09/23/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250550
Principal investigator 1 GlaxoSmithKline, LLC. $0.20 09/03/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROU No dispute reported 06/30/2026 1192168029
Principal investigator 1 Madrigal Pharmaceuticals $2,113.95 08/26/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248249070
Principal investigator 1 Madrigal Pharmaceuticals $2,113.95 08/21/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248850
Principal investigator 1 GlaxoSmithKline, LLC. $14,480.00 08/07/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192168041
Principal investigator 1 GlaxoSmithKline, LLC. $2,824.00 08/07/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192168565
Principal investigator 1 Boehringer Ingelheim International GmbH $80.60 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638071
Principal investigator 1 Boehringer Ingelheim International GmbH $135.20 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638073
Principal investigator 1 Boehringer Ingelheim International GmbH $117.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638075
Principal investigator 1 Boehringer Ingelheim International GmbH $78.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638077
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638079
Principal investigator 1 Boehringer Ingelheim International GmbH $7,150.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638081
Principal investigator 1 Boehringer Ingelheim International GmbH $28.60 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638083
Principal investigator 1 Boehringer Ingelheim International GmbH $76.70 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638085
Principal investigator 1 Boehringer Ingelheim International GmbH $80.60 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638087
Principal investigator 1 Boehringer Ingelheim International GmbH $135.20 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638089
Principal investigator 1 Boehringer Ingelheim International GmbH $117.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638091
Principal investigator 1 Boehringer Ingelheim International GmbH $78.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638093
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638095
Principal investigator 1 Boehringer Ingelheim International GmbH $28.60 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638097
Principal investigator 1 Boehringer Ingelheim International GmbH $76.70 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638099
Principal investigator 1 Boehringer Ingelheim International GmbH $80.60 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638101
Principal investigator 1 Boehringer Ingelheim International GmbH $135.20 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638103
Principal investigator 1 Boehringer Ingelheim International GmbH $117.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638105
Principal investigator 1 Boehringer Ingelheim International GmbH $78.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638107
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638109
Principal investigator 1 Boehringer Ingelheim International GmbH $28.60 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638111
Principal investigator 1 Boehringer Ingelheim International GmbH $76.70 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638113
Principal investigator 1 Boehringer Ingelheim International GmbH $80.60 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638115
Principal investigator 1 Boehringer Ingelheim International GmbH $135.20 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638117
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638119
Principal investigator 1 Boehringer Ingelheim International GmbH $28.60 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638121
Principal investigator 1 Boehringer Ingelheim International GmbH $76.70 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638123
Principal investigator 1 Boehringer Ingelheim International GmbH $80.60 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638125
Principal investigator 1 Boehringer Ingelheim International GmbH $135.20 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638127
Principal investigator 1 Boehringer Ingelheim International GmbH $117.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638129
Principal investigator 1 Boehringer Ingelheim International GmbH $78.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638131
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638133
Principal investigator 1 Boehringer Ingelheim International GmbH $28.60 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638135
Principal investigator 1 Boehringer Ingelheim International GmbH $76.70 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638137
Principal investigator 1 Boehringer Ingelheim International GmbH $135.20 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638139
Principal investigator 1 Boehringer Ingelheim International GmbH $117.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638141
Principal investigator 1 Boehringer Ingelheim International GmbH $78.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638143
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638145
Principal investigator 1 Boehringer Ingelheim International GmbH $28.60 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638147
Principal investigator 1 Boehringer Ingelheim International GmbH $76.70 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638149
Principal investigator 1 Boehringer Ingelheim International GmbH $325.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638151
Principal investigator 1 Boehringer Ingelheim International GmbH $80.60 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638153
Principal investigator 1 Boehringer Ingelheim International GmbH $117.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638155
Principal investigator 1 Boehringer Ingelheim International GmbH $78.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638157
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638159
Principal investigator 1 Boehringer Ingelheim International GmbH $28.60 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638161
Principal investigator 1 Boehringer Ingelheim International GmbH $76.70 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638163
Principal investigator 1 Boehringer Ingelheim International GmbH $80.60 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638165
Principal investigator 1 Boehringer Ingelheim International GmbH $135.20 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638167
Principal investigator 1 Boehringer Ingelheim International GmbH $117.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638169
Principal investigator 1 Boehringer Ingelheim International GmbH $78.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638171
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638173
Principal investigator 1 Boehringer Ingelheim International GmbH $28.60 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638175
Principal investigator 1 Boehringer Ingelheim International GmbH $76.70 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638177
Principal investigator 1 Boehringer Ingelheim International GmbH $80.60 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638179
Principal investigator 1 Boehringer Ingelheim International GmbH $135.20 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638181
Principal investigator 1 Boehringer Ingelheim International GmbH $117.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638183
Principal investigator 1 Boehringer Ingelheim International GmbH $78.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638185
Principal investigator 1 Boehringer Ingelheim International GmbH $351.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638187
Principal investigator 1 Boehringer Ingelheim International GmbH $522.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638189
Principal investigator 1 Boehringer Ingelheim International GmbH $360.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638191
Principal investigator 1 Boehringer Ingelheim International GmbH $240.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638193
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638195
Principal investigator 1 Boehringer Ingelheim International GmbH $1,350.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638197
Principal investigator 1 Boehringer Ingelheim International GmbH $325.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638199
Principal investigator 1 Boehringer Ingelheim International GmbH $135.20 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638201
Principal investigator 1 Boehringer Ingelheim International GmbH $117.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638203
Principal investigator 1 Boehringer Ingelheim International GmbH $78.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638205
Principal investigator 1 Boehringer Ingelheim International GmbH $130.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638207
Principal investigator 1 Boehringer Ingelheim International GmbH $7,150.00 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638209
Principal investigator 1 Boehringer Ingelheim International GmbH $28.60 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638211
Principal investigator 1 Boehringer Ingelheim International GmbH $76.70 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638213
Principal investigator 1 Boehringer Ingelheim International GmbH $80.60 07/30/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638215
Principal investigator 1 Madrigal Pharmaceuticals $4,227.90 07/22/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247382
Principal investigator 1 Madrigal Pharmaceuticals $13,547.25 07/04/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246453
Principal investigator 1 Madrigal Pharmaceuticals $100.00 07/04/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246457
Principal investigator 1 Madrigal Pharmaceuticals $2,428.29 07/04/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246461
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 07/01/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638217
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 06/24/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220638027
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 06/24/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638067
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 06/24/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638069
Principal investigator 1 Madrigal Pharmaceuticals $7,284.87 06/12/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248245578
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 06/01/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638219
Principal investigator 1 Genentech, Inc. $3,000.00 05/28/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211612829
Principal investigator 1 Genentech, Inc. $14,300.00 05/28/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211612833
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 05/27/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220638025
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 05/27/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638063
Principal investigator 1 Boehringer Ingelheim International GmbH $29.31 05/27/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638065
Principal investigator 1 Genentech, Inc. $4,138.00 05/27/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) No dispute reported 06/30/2026 1211612825
Principal investigator 1 GlaxoSmithKline, LLC. $3,402.00 05/16/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192168569
Principal investigator 1 GlaxoSmithKline, LLC. $1,263.00 05/16/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192168573
Principal investigator 1 GlaxoSmithKline, LLC. $402.00 05/16/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192168577
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 05/01/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638061
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 04/23/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220638021
Principal investigator 1 Boehringer Ingelheim International GmbH $8,000.00 04/23/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220638023
Principal investigator 1 Boehringer Ingelheim International GmbH $8,000.00 04/23/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638049
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 04/23/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638059
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 04/01/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638045
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 03/25/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638043
Principal investigator 1 Genentech, Inc. $3,000.00 03/14/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211612812
Principal investigator 1 Genentech, Inc. $2,838.00 03/14/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211612816
Principal investigator 1 Genentech, Inc. $15,600.00 03/14/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2) No dispute reported 06/30/2026 1211612822
Principal investigator 1 Madrigal Pharmaceuticals $2,550.38 03/06/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240377
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 03/01/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638047
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638051
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 03/01/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638053
Principal investigator 1 Boehringer Ingelheim International GmbH $125.00 03/01/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638055
Principal investigator 1 Boehringer Ingelheim International GmbH $28.00 03/01/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638057
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 02/25/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638039
Principal investigator 1 Boehringer Ingelheim International GmbH $547.50 02/25/2025 Non-covered Recipient Entity
Jorge R Beato MD PA
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220638041
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 02/06/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192168033
Principal investigator 1 Madrigal Pharmaceuticals $6,341.85 02/06/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239192
Principal investigator 1 Madrigal Pharmaceuticals $10,013.26 01/03/2025 Non-covered Recipient Entity
HI TECH AND GLOBAL RESEARCH LLC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248237951